Exelixis (EXEL) Return on Sales [ROS] (2010 - 2026)
Exelixis (EXEL) recorded Return on Sales [ROS] of 39.51% in Q2 2027, up 1.93 percentage points from 37.58% a year earlier but down 1.64 percentage points from the prior quarter.
Powered by 
Analysis
Exelixis (EXEL) Return on Sales [ROS] (2010 - 2026) Analysis & Trends
On a TTM basis, Exelixis' Return on Sales [ROS] came in at 39.88% as of Jul 3, 2026, up 8.51 percentage points year-over-year; for FY2026, it came in at 37.59%, up 9.71 percentage points from FY2025.
- Annual Return on Sales [ROS] has a five-year change of +17.62 percentage points (FY2021 to FY2026).
- Across earlier years, Return on Sales [ROS] came in at 27.88% in FY2025, 9.34% in FY2023 (-3.17 pp) and 12.51% in FY2022 (-7.47 pp).
- Quarterly Return on Sales [ROS] has ranged from 6.93% in Q1 2025 to 43.30% in Q2 2025 over the past five years.
- On a year-over-year basis, Return on Sales [ROS] has increased for four consecutive quarters, with an average year-over-year change of +9.21 percentage points over the last six quarters.
- Per Business Quant, the preceding three quarters came in at 41.15% (Q1 2027), 39.29% (Q4 2026) and 39.57% (Q3 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Exelixis | 14.53 Bn | 10.87 Bn | 608.03 Mn | 39.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 39.51% |
| Apr 3, 2026 | 41.15% |
| Jan 2, 2026 | 39.29% |
| Oct 3, 2025 | 39.57% |
| Jul 4, 2025 | 37.58% |
| Apr 4, 2025 | 33.64% |
| Jan 3, 2025 | 28.80% |
| Sep 27, 2024 | 25.22% |
| Jun 28, 2024 | 43.30% |
| Mar 29, 2024 | 6.93% |
| Dec 29, 2023 | 17.05% |
| Sep 29, 2023 | -3.73% |
| Jun 30, 2023 | 16.57% |
| Mar 31, 2023 | 7.05% |
| Dec 30, 2022 | -11.34% |
| Sep 30, 2022 | 20.06% |
| Jul 1, 2022 | 19.96% |
| Apr 1, 2022 | 23.38% |
| Oct 1, 2021 | 15.72% |
| Jul 2, 2021 | 31.94% |
API Access
Exelixis Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=EXEL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "EXEL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=EXEL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();